Join to View Full Profile
200 W Arbor DrMC 8409San Diego, CA 92103
Phone+1 619-543-4619
Dr. Ginsberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2012 - 2015- Washington University in St. Louis School of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2015 - 2026
MO State Medical License 2014 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Clinical Trials
- Phosphate Microvascular Study Start of enrollment: 2019 Jan 01
Publications & Presentations
PubMed
- The Difference in Cystatin C- and Creatinine-Based eGFR and Cognition in MrOS.Lindsay M Miller, O Alison Potok, Dena E Rifkin, Kristine Yaffe, Kristine Ensrud
Kidney360. 2025-03-11 - Serum free 25(OH)D concentrations and cardiovascular disease, heart failure, kidney function decline, and fracture: the health, aging, and body composition study.Jonathan H Cheng, Andrew N Hoofnagle, Ronit Katz, Stephen B Kritchevsky, Michael G Shlipak
JBMR Plus. 2025-03-01 - 1 citationsAcetazolamide Therapy and Kidney Function in Persons with Nonalbuminuric Diabetes Mellitus Type 1.Charles Ginsberg, Jesse C Seegmiller, Volker Vallon, Sami SeungMi Jin, Robert L Thomas
Journal of the American Society of Nephrology. 2025-03-01
Journal Articles
- PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINTUdayan Y Bhatt, Clinton B Wright, Vasilios Papademetriou, Joachim H Ix, Michael G Shlipak, Alfred K Cheung, Mark J Sarnak, Jing Chen, Charles Ginsberg, Glenn M Chertow..., Journal of the American Society of Nephrology
Press Mentions
Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial ResultsAugust 11th, 2021- Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging AgentMay 11th, 2021
Elevated Phosphate May Be Detrimental Even Without CKDOctober 14th, 2019
Grant Support
- Renal Molecular Imaging of Mesangial Cell Function with Tc-99m-TilmanoceptUNIVERSITY OF CALIFORNIA, SAN DIEGO2021–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
